Pfizer COVID-19 Vaccine Status Livestream Event With Shook Public Policy Partners
Lawyers for Civil Justice (LCJ) will present a free livestream presentation November 17, 3:00 p.m. EST, discussing the Pfizer COVID-19 vaccine found to be 90% effective in preventing the virus in participants in a recent Phase 3 clinical study.
Co-Chairs of Shook’s Public Policy Practice Group Mark Behrens and Victor E. Schwartz will serve as moderator and panelist, respectively, in the live presentation along with panelists Assistant General Counsel for Pfizer, Inc., Markus Green and Senior Republican Counsel for the Committee on Oversight and Government Reform in the U.S. House of Representatives Paul Brian Taylor.
The Pfizer and BioNTech vaccine candidate, BNT162b2 is expected to be submitted in the third week of November for Emergency Use Authorization (EUA) to U.S. Food and Drug Administration (FDA). The vaccine will require two months of additional safety data plus rigorous examination by FDA, but its high efficacy rate and test results make it the most promising vaccine for combating COVID-19 to date.
As the first vaccine to approach deployment and public use in the U.S., this live presentation will hone in on the Public Readiness and Emergency Preparedness Act (PREP Act) and the liability issues that will come with the potential rollout and release of this vaccine to the public.
Co-Chairs of Shook’s Public Policy Practice Group Mark Behrens and Victor E. Schwartz will serve as moderator and panelist, respectively, in the live presentation along with panelists Assistant General Counsel for Pfizer, Inc., Markus Green and Senior Republican Counsel for the Committee on Oversight and Government Reform in the U.S. House of Representatives Paul Brian Taylor.
The Pfizer and BioNTech vaccine candidate, BNT162b2 is expected to be submitted in the third week of November for Emergency Use Authorization (EUA) to U.S. Food and Drug Administration (FDA). The vaccine will require two months of additional safety data plus rigorous examination by FDA, but its high efficacy rate and test results make it the most promising vaccine for combating COVID-19 to date.
As the first vaccine to approach deployment and public use in the U.S., this live presentation will hone in on the Public Readiness and Emergency Preparedness Act (PREP Act) and the liability issues that will come with the potential rollout and release of this vaccine to the public.
